Clinician’s Update on Omega-3s in ASCVD Risk Reduction - a podcast by ReachMD

CME credits: 0.25

Valid until: 26-07-2022

Claim your CME credit at https://reachmd.com/programs/cme/clinicians-update-omega-3s-ascvd-risk-reduction/12718/

More than 15 professional societies now recommend the use of icosapent ethyl to treat atherosclerotic cardiovascular disease (ASCVD), but clinical questions about the use of omega-3 fatty acids remain. Dr. Leslie Cho and Dr. Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more!

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD